Cuba’s Abdala coronavirus candidate vaccine shows more than 92 per cent efficacy after three doses, its maker says.
- Cuba is developing five vaccines, including two that are already being rolled out to the population
- The BioCubaFarma laboratory says the Abdala vaccine is 92.28 per cent effective
- Cuba’s president says the development will “multiply pride” in the island nation
Cuba is working on five coronavirus vaccines. It last month started immunising its population using two of them yet to complete clinical trials.
The BioCubaFarma laboratory wrote on Twitter on Monday that Abdala — one of the two already in use — showed “an efficacy of 92.28 per cent in its three-dose scheme”.
It did not specify whether this was measured against infection, disease, or death, however.
The World Health Organization has set a 50 per cent efficacy threshold for coronavirus vaccines to offer protection against the virus or disease.
The announcement came two days after authorities announced that Soberana 2, the other three-dose shot being developed in Cuba, was 62 per cent effective after the first two shots.
Cuban President Miguel Diaz-Canel welcomed the news as an achievement that “will multiply pride” in the communist island nation.
Cuba has been relatively unscathed by the outbreak but has seen a recent sharp increase in cases.
Francisco Duran, the island’s director of epidemiology, on Monday reported 1,561 new COVID-19 infections for a total of 169,365 confirmed cases and 1,170 deaths.
Under American sanctions, Cuba has a long tradition of making its own vaccines, dating back to the 1980s.
Nearly 80 per cent of its vaccines are produced locally and it hopes to come up with the first locally produced coronavirus shot in Latin America.
What you need to know about coronavirus: